Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOBI002 in healthy volunteers
NCT02083666Phase 1Terminated
- Sponsor
- Sobi
- Start
- Dec 2013
- Primary completion
- Nov 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in paroxysmal nocturnal hemoglobinuria (PNH) comparing SOBI002 with placebo (2 arms). Primary endpoint: Safety and Tolerability at 13 weeks. Started Dec 2013; status: terminated.
02
Drugs
SOBI002
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT02083666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02083666.